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Introduction
Spinal muscular atrophy (SMA) is the leading genetic cause 
of infant mortality, with an incidence of approximately one in 
6,000–10,000 newborns (Arnold and Burghes, 2013; Nurputra 
et al., 2013). SMA is an autosomal recessive neuromuscular 
disorder primarily characterized by degeneration of spinal cord 
motor neurons and consequent atrophy of skeletal muscles. The 
disease is most commonly caused by homozygous deletion of 
the Survival Motor Neuron 1 (SMN1) gene, leading to reduced 
levels of the ubiquitously expressed SMN protein (Arnold and 
Burghes, 2013; Nurputra et al., 2013). SMN plays key roles in 
several canonical cellular pathways, including biogenesis of the 
small nuclear RNPs, which are core components of the spli-
ceosome (Wahl et al., 2009), pre-mRNA splicing, and RNA 
transport (Li et al., 2014). Nevertheless, attempts to directly link 
aberrant RNA processing with SMA pathogenesis have proven 
controversial (Zhang et al., 2008; Bäumer et al., 2009).
SMA patients retain at least one copy of the almost iden-
tical SMN2 gene. However, although it encodes a virtually iden-
tical protein, the expression levels of SMN2 are not sufficient to 
restore full SMN activity (Arnold and Burghes, 2013; Nurputra 
et al., 2013). The coding regions of SMN1 and SMN2 differ only 
for a silent C to T transition at position 6 in exon 7, leading to the 
skipping of exon 7 in most SMN2 transcripts and to production 
of an unstable SMNΔ7 protein that is rapidly degraded (Burnett 
et al., 2009; Cho and Dreyfuss, 2010). The residual low levels 
of SMN2 transcripts that include exon 7 produce small amounts 
of fully functional SMN protein, supporting early development 
and viability in patients and mouse models of SMA (Arnold 
and Burghes, 2013; Nurputra et al., 2013). Currently, there is no 
cure for SMA patients (Lorson and Lorson, 2012; Arnold and 
Burghes, 2013). Because rescue of exon 7 splicing represents a 
suitable therapeutic approach for SMA, understanding the mo-
lecular mechanisms involved in the regulation of this splicing 
event is of fundamental importance.
Many RNA-binding proteins (RBPs) have been pro-
posed to play a role in the regulation of SMN2 splicing in vitro 
(Hofmann et al., 2000; Hofmann and Wirth, 2002; Kashima and 
Manley, 2003; Kashima et al., 2007; Bose et al., 2008; Chen et 
al., 2008; Pedrotti et al., 2010; Singh et al., 2011), including 
hnRNP A1 (Kashima and Manley, 2003; Kashima et al., 2007) 
and SAM68 (Pedrotti et al., 2010), suggesting that the relative 
expression levels or activity of specific splicing factors can 
modulate SMN2 splicing (Pedrotti and Sette, 2010). However, 
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whether any of these regulators play a role in vivo and contrib-
ute to the SMA phenotype is still currently unknown.
Herein, we have investigated the role of SAM68—a mem-
ber of the signal transduction and activation of RNA family of 
RBPs (Lukong and Richard, 2003; Bielli et al., 2011)—in the 
regulation of SMN2 splicing in vivo by using the SMAΔ7 mouse 
model (Le et al., 2005). We show that SAM68 binds the exon 7 
region of SMN2 pre-mRNA in vivo, promoting recruitment of 
the splicing repressor hnRNP A1 and interfering with binding of 
the general splicing factor U2AF65. Ablation of SAM68 activity 
was accompanied by a partial recovery in body weight, viability, 
and motility of SMAΔ7 mice. These effects correlated with regu-
lation of SMN2 splicing, as knockout of Sam68 increased exon 7 
inclusion and SMN expression in the cortex, cerebellum, spinal 
cord, and peripheral tissues of SMAΔ7 mice. Recovery of SMN 
expression resulted in an increase in nuclear gems in spinal cord 
motor neurons and in reduction of motor neuron loss, leading to 
significant amelioration of SMA-related defects in neuromus-
cular junctions (NMJs), skeletal muscles, and other peripheral 
organs. This work provides the first evidence of a splicing factor 
that modulates SMN2 splicing and SMN expression in vivo, thus 
affecting the phenotype of an SMA mouse model.
Results
SAM68 binds SMN2 exon 7 and mediates 
recruitment of hnRNP A1 in vivo
In cultured cells, SAM68 binds the SMN2-specific exonic 
splicing silencer created by the C to T transition in exon 7 
(UUU UA), thus repressing its recognition by the spliceosome 
through recruitment of the splicing repressor hnRNP A1 and 
causing exon skipping in transfected cells and in SMA fibro-
blasts in culture (Pedrotti et al., 2010). To determine whether 
SAM68 binds SMN2 exon 7 also in a physiological context, we 
performed UV–cross-linking immunoprecipitation (CLIP) ex-
periments in the brain of non-SMA (SMN2Δ7;SMN2;Smn+/+) 
mice that are either wild type (Sam68+/+) or knockout 
(Sam68−/−) for Sam68. CLIP assays were evaluated by quan-
titative real-time PCR (qPCR) using primers spanning the 
SMN2 transcription unit (Fig.  1  A). SAM68 was recruited 
to the transgenic human SMN2 pre-mRNA in the Sam68+/+ 
brain, with a strong enrichment at the intron 6–exon 7 junc-
tion (I6/E7), whereas binding was reduced in the downstream 
junction (E7/I7) and in the upstream exons 3 and 5 (Fig. 1 B). 
SAM68 signals detected by CLIP assays were specific, as 
demonstrated by the strongly reduced or absent binding ob-
served in SMN2Δ7;SMN2;Smn+/+ mice that are knocked out 
for Sam68 (Sam68−/−) (Fig. S1 A). Importantly, hnRNP A1 
was efficiently recruited to the exon 7 region of the SMN2 
pre-mRNA in Sam68+/+ mice, but its binding was strongly im-
paired in Sam68−/− mice (Fig. 1 C). These results suggest that 
binding of SAM68 to the intron 6–exon 7 junction of SMN2 
pre-mRNA favors the recruitment of a splicing repressor in a 
physiological context of relevance for SMA.
U2AF65 is a general splicing factor that favors assem-
bly of the U2 small nuclear RNP to the 3′ splice site (ss) and 
promotes exon definition (Wahl et al., 2009). Because SAM68 
binds near the 3′ ss of exon 7 (Fig. 1 B), we tested whether it 
competes with recruitment of U2AF65 by performing in vitro 
pull-down assays using RNA-biotinylated probes of the SMN2 
exon 7 region with the flanking 3′ intron including the branch 
site (Fig. 1 D; Pedrotti et al., 2010). A streptavidin pull-down 
assay using brain nuclear extracts showed that knockout of 
Sam68 expression increased recruitment of U2AF65 to SMN2 
exon 7 RNA (Fig. 1 E). Conversely, overexpression of FLAG-
SAM68 in HEK293T interfered with binding of endogenous 
U2AF65 to the 3′ ss (Fig. 1 F).
These experiments indicate that binding of SAM68 to 
SMN2 exon 7 favors the recruitment of a splicing repressor 
while counteracting that of a positive splicing regulator.
Ablation of Sam68 expression partially 
rescues viability, body weight, and motor 
function of SMAΔ7 mice
SMAΔ7 mice carry a homozygous deletion of the mouse Smn 
gene, two copies of the human SMN2 transgene, and the human 
SMN2Δ7 cDNA (SMN2Δ7;SMN2;Smn−/−; Le et al., 2005). To 
investigate whether SAM68 plays a role in SMA, we crossed 
SMN2Δ7;SMN2;Smn+/− mice with Sam68+/− mice (Fig. 2 A). 
Heterozygote mice were used because Sam68−/− males are 
sterile (Paronetto et al., 2009) and females are subfertile (Bi-
anchi et al., 2010). Genotyping of the offspring confirmed that 
double knockout mice (SMN2Δ7;SMN2;Smn−/−;Sam68−/−) 
were born (Fig. 2 A). A backcross of heterozygote mice was 
performed to obtain SMN2Δ7 homozygous transgenic an-
imals, as determined by qPCR measurement of SMN2Δ7 
expression (Fig. 2 B).
Comparison of viability and body weight of the 
SMAΔ7/Sam68+/+ (SMN2Δ7;SMN2;Smn−/−;Sam68+/+) and 
SMAΔ7/Sam68−/− (SMN2Δ7;SMN2;Smn−/−;Sam68−/−) mice 
revealed that ablation of SAM68 function affected the phe-
notype of SMA mice (Fig.  2  C). SMAΔ7/Sam68+/+ mice 
displayed a maximum survival of 14 d (mean survival = 
11 d), whereas SMAΔ7/Sam68−/− displayed a maximum sur-
vival of 20 d (mean survival = 16 d; Fig.  2  D). Thus, inhi-
bition of SAM68 function in vivo significantly extended the 
life span of SMAΔ7 mice.
The first phenotypic difference between SMAΔ7/
Sam68+/+ and SMAΔ7/Sam68−/− mice was body size (Fig. 2, C 
and E). The reduced weight of SMAΔ7 mice was first appreci-
ated at 5 d postpartum (dpp; Le et al., 2005). We found that the 
weight of SMAΔ7/Sam68+/+ did not increase significantly from 
5 dpp to death; in contrast, SMAΔ7/Sam68−/− mice steadily in-
creased in size until 11 dpp, after which body weight started 
to decline (Fig. 2 E). Importantly, Sam68−/− mice are smaller 
than wild-type littermates (Fig. 2, C and E), indicating that this 
phenotype might partially limit the recovery in body weight ob-
served in the SMAΔ7 context.
Next, we measured the motor function of the experimen-
tal mice. SMAΔ7/Sam68−/− mice at 8 and 10 dpp displayed 
less difficulty than SMAΔ7/Sam68+/+ littermates in righting 
when placed on their sides (Fig.  2  F). At 8 dpp, 11 out of 
12 SMAΔ7/Sam68−/− mice were able to right themselves, 
whereas 60% of the SMAΔ7/Sam68+/+ (n = 10) could not, 
and the rest were slower (Fig. 2 F). The difference was main-
tained at 10 dpp, when five out of six SMAΔ7/Sam68−/− mice 
were able to right themselves in the time frame of the test, 
whereas none of the SMAΔ7/Sam68+/+ mice did (Fig.  2  F). 
Non-SMA Sam68−/− mice could readily right themselves at 
these ages (Fig. S1 B).
These results suggest that deletion of SAM68 func-
tion partially rescues postnatal development and the 
life span of SMAΔ7 mice.
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Figure 1. SAM68 binds SMN2 exon 7 and mediates recruitment of hnRNP A1 in vivo. (A) Schematic representation of the human SMN2 gene. Boxes 
represent exons, black lines represent introns, and the red box indicates the regulated exon 7. Red arrows indicate the oligonucleotide pairs used in the 
analysis. (B) CLIP assay of SAM68-bound SMN2 pre-mRNA in brain of non-SMA mice (SMN2Δ7;SMN2;Smn+/+). (C) CLIP assay of hnRNP A1 in brain 
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Sam68 deletion rescues SMN2 splicing 
and expression in SMAΔ7 tissues
We then tested whether the partial rescue of the phenotype 
observed in SMAΔ7/Sam68−/− mice correlated with improve-
ment of SMN2 splicing and expression. To this end, cortex, 
cerebellum, spinal cord, liver, heart, kidney, and lung sam-
ples from 10-dpp SMAΔ7/Sam68+/+ and SMAΔ7/Sam68−/− 
mice were collected for qPCR and Western blot analyses. 
Remarkably, Sam68 ablation resulted in an increase of exon 
7 inclusion in all tissues analyzed (Fig.  3  A). Normaliza-
tion of SMN2 exon 6 expression with Actin mRNA showed 
that there was no general increase in SMN2 transcription 
(Fig. S2 A), ruling out increased transcription or stability 
as part of the mechanism. Improved SMN2 exon 7 splicing 
correlated with an increase in SMN protein expression in 
SMAΔ7/Sam68−/− mice with respect to SMAΔ7/Sam68+/+ 
littermates, particularly in cortex and cerebellum (Fig. 3 B; 
and Fig. S2, B and C). Expression of GEM IN2, which is de-
graded when the SMN complex is less abundant and/or func-
tionally impaired (Feng et al., 2005), was also significantly 
increased in cortex and cerebellum of SMAΔ7/Sam68−/− 
with respect to those of SMAΔ7/Sam68+/+ mice (Fig. S2, B 
and C). Conversely, ablation of Sam68 in a non-SMA con-
text, where the SMN1-like murine Smn gene contributes to 
the large majority of SMN protein expression, did not exert 
any effect (Fig. S2 D), indicating that SAM68 specifically 
functions on the human SMN2 transgene.
Ablation of Sam68 rescues SMN 
assembly into nuclear gems in spinal cord 
motor neurons
The SMA phenotype is mainly caused by degeneration of 
motor neurons in the spinal cord as a consequence of low 
SMN expression (Arnold and Burghes, 2013; Nurputra et al., 
2013). Notably, we found that SAM68 is expressed at much 
higher levels in motor neurons than in the surrounding cells 
of the spinal cord (Fig. 4 A). Thus, we set out to investigate 
whether loss of SAM68 function affected the expression of 
SMN in motor neurons. Because SMN levels and function-
ality correlate with its accumulation in nuclear structures 
named gems (Li et al., 2014), we tested whether SAM68 ex-
pression affected its subcellular localization. Spinal cords 
from 8-dpp non-SMA, SMAΔ7/Sam68+/+, and SMAΔ7/
Sam68−/− mice were collected and stained for SMN and for 
the motor neuron marker choline acetyltransferase (ChAT). 
As expected (Branchu et al., 2013), SMN gems were almost 
absent in most motor neurons of SMAΔ7 mice (Fig.  4, B 
and C). However, knockout of Sam68 significantly increased 
the number of gems per motor neuron and the percentage of 
gem-containing motor neurons (Fig. 4, B and C), indicating 
that the increase in SMN protein expression was functionally 
relevant in the spinal cord.
Ablation of Sam68 rescues motor neuron 
loss in the spinal cord of SMAΔ7 mice
Progressive degeneration of motor neurons in the ventral horns 
of the spinal cord is the main hallmark of SMA (Arnold and 
Burghes, 2013; Nurputra et al., 2013). To test whether inhibi-
tion of SAM68 function affected the number of motor neurons 
in SMAΔ7 mice, coronal sections of the lumbar spinal cord 
(L1–L5) were stained with Nissl substance (Fig. 5, A and B). 
An unbiased count of the total number of motor neurons (see 
Materials and methods section Motor neuron count in lumbar 
spinal cord) indicated that SMAΔ7 mice displayed >50% re-
duction in the number of motor neurons at 8 dpp with respect to 
non-SMA mice (Fig. 5, B and C). In line with the recovery in 
SMN expression and nuclear gems assembly, ablation of Sam68 
significantly promoted maintenance of motor neurons (Fig. 5, B 
and C), confirming that the rescue of SMN expression in these 
cells was functionally relevant.
Innervation of NMJs is ameliorated in 
SMAΔ7/Sam68−/− mice
Several axial and appendicular muscles of SMAΔ7 mice dis-
play denervation of NMJs (Ling et al., 2012). Thus, we tested 
whether Sam68 expression affected the proper innervation 
of NMJs in muscles of 10-dpp non-SMA and SMAΔ7 mice. 
Motor endplates were identified by confocal analyses with flu-
orophore-conjugated α-bungarotoxin, which specifically stains 
the subunit of acetylcholine receptors (AChRs), and nerve ter-
minals were stained with antisynaptophysin and with an anti-
body directed against neurofilament heavy chains (Le et al., 
2005; Hua et al., 2011). Analysis of the flexor digitorum brevis 
2 (FDB2), one of the most vulnerable appendicular muscles in 
SMAΔ7 mice (Ling et al., 2012), showed a twofold increase 
in denervated NMJs in SMAΔ7/Sam68+/+ mice compared with 
age-matched non-SMA mice (Fig.  6, A and B). Importantly, 
this defect was rescued in the SMAΔ7/Sam68−/− mice (Fig. 6, 
A and B). No significant difference in NMJ innervation was 
observed in FDB2 muscles from non-SMA mice that were ei-
ther wild type or knockout for Sam68 (Fig. 6 B). The rescue 
of innervation in SMAΔ7/Sam68−/− mice was also observed 
in the masseter (Fig. S3, A and B), one of the most vulnerable 
axial muscles in SMAΔ7 mice (Ling et al., 2012). These results 
indicate that Sam68 depletion improves innervation of NMJs 
in a mouse model of SMA.
Skeletal muscle atrophy and peripheral 
organ phenotypes are improved in SMAΔ7/
Sam68−/− mice
NMJ denervation in SMAΔ7 mice leads to skeletal muscle at-
rophy without showing dystrophic features (Le et al., 2005). 
Consistently, as shown by the frequency distribution of the 
cross-sectional area (CSA), myofibers from triceps of 10-dpp 
SMAΔ7/Sam68+/+ mice were significantly smaller than those 
of non-SMA mice that are wild type or knockout for Sam68. Signals for SAM68 (B) and hnRNP A1 (C) binding was calculated as fold enrichment versus 
IgGs and expressed as mean ± SD; n = 3. The p-value was determined by two-tailed t test (B) or one-way ANO VA test followed by Bonferroni’s multiple 
comparison posttest (C). *, P < 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; n.s., not significant (P > 0.05). (D) Sequence of human SMN2 probe used to synthe-
size the biotinylated RNA for the streptavidin pull-down experiment. Lowercase letters indicate the intron 6 sequence; uppercase letters indicate the exon 
7 sequence. Bold letters and red arrows indicate primers used to synthesize the probe, and red bold letters indicate the exonic splicing silencers created 
by the C to T transition in SMN2 to which SAM68 binds. (E and F) Western blot analysis of the binding of endogenous U2AF65 to the biotinylated probe 
(SMN2 Ex7) in streptavidin pull-down assays using brain extracts from non-SMA Sam68+/+ (wt) or Sam68−/− (ko) mice (E) or extracts from HEK293T cells 
transfected (+) or not (−) with FLAG-SAM68 (F). Results are representative of three experiments that yielded similar results. ko, knockout; N.E., nuclear 
extracts; wt, wild type.
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Figure 2. Ablation of Sam68 expression partially rescues viability, body weight, and motor function of SMAΔ7 mice. (A) Schematic diagram of transgenic 
mice crossing (top) and PCR analysis of genomic DNA (bottom) from tails of SMN2Δ7;SMN2;Smn+/+;Sam68+/+ (first lane), SMN2Δ7;SMN2;Smn−/−;Sam68+/+ 
(second lane), and SMN2Δ7;SMN2;Smn−/−;Sam68−/− (third lane) mice. Bands showing the transgenic and endogenous DNA bands amplified are indi-
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of non-SMA littermates (Fig.  7, A and B). Notably, muscles 
of SMAΔ7/Sam68−/− mice were characterized by bigger myofi-
bers than those of SMAΔ7/Sam68+/+ littermates (Fig. 7, A and 
B), with the frequency distribution of CSA revealing a signif-
icant shift of the median value toward the larger size of fibers 
(Fig. 7 B). In non-SMA mice, knockout of Sam68 did not affect 
the size of myofibers (Fig. 7 B).
Skeletal muscle atrophy in SMA mice is accompanied 
by elevated expression of atrophy-related genes (Bricceno et 
al., 2012). The transcription factors FoxO3 and NF-κB are in-
volved in activation of the ubiquitin–proteasome system and 
autophagy (Cai et al., 2004; Mammucari et al., 2007), two 
important intracellular degradation mechanisms responsi-
ble for skeletal muscle atrophy. Thus, we analyzed targets of 
FoxO3 and NF-κB (Cai et al., 2004; Mammucari et al., 2007), 
such as Trim63/MuRF1, Atrogin1/MAFbx, and Cathepsin L, 
in SMAΔ7/Sam68+/+ and SMAΔ7/Sam68−/− mice. Trim63, 
Atrogin1, and Cathepsin L were significantly up-regulated in 
muscles of SMAΔ7/Sam68+/+ mice; however, their expres-
sion was reduced to the levels of control mice in muscles from 
SMAΔ7/Sam68−/− mice (Fig. 7 C). Expression of these genes 
was not affected in non-SMA Sam68−/− mice (Fig. 7 C). These 
findings indicate that ablation of Sam68 rescues skeletal mus-
cle atrophy in SMAΔ7 mice.
SMA mouse models also display defects in peripheral or-
gans, such as the liver (Hua et al., 2011) and heart (Shababi et al., 
2010). For instance, decreased expression of hepatic insulin-like 
growth factor (IGF)–binding protein acid labile subunit (Igfals) 
in neonatal SMA mice caused pronounced reduction of circulat-
ing IGF-1, which was suggested to contribute to the phenotype 
(Hua et al., 2011). Expression of Igf-1 and Igfals was strongly 
reduced in the liver of 10-dpp SMAΔ7/Sam68+/+ mice, whereas 
this defect was attenuated in SMAΔ7/Sam68−/− mice (Fig. S4 A). 
Moreover, histological examination showed hepatic steatosis 
accompanied by an influx of inflammatory cells in SMAΔ7/
Sam68+/+ mice, but not in the liver of SMAΔ7/Sam68−/− mice, 
which resembled that of control mice (Fig. S4 B).
SMA mice show signs of oxidative stress in the heart, such 
as elevated expression of Angiotensin 1 receptor (AT1R), Rac1, 
and Nox2 (Shababi et al., 2010). Expression of AT1R and Rac1 
was increased in the liver (Fig. S4 C) and heart (Fig. S4 D) of 
SMAΔ7/Sam68+/+ mice, whereas Nox2 was up-regulated only 
in the heart (Fig. S4 D). SMAΔ7/Sam68−/− mice showed lower 
expression levels of AT1R and Rac1 in these organs (Fig. S4, 
C and D), resembling those of non-SMA mice. None of these 
parameters in peripheral organs were affected in non-SMA 
Sam68−/− mice (Fig. S4, A, C, and D; and unpublished data).
The thickness of the interventricular septum (IVS) is re-
duced in SMA mice (Shababi et al., 2010; Hua et al., 2011). 
Accordingly, SMAΔ7/Sam68+/+ mice showed an ∼60% re-
duction in IVS thickness compared with the non-SMA litter-
mates, whereas this reduction was partially compensated for in 
SMAΔ7/Sam68−/− mice (Fig. S4 E). Collectively, these results 
indicate that ablation of Sam68 also improves defects in the pe-
ripheral organs of SMAΔ7 mice.
Discussion
Our work identifies SAM68 as a physiological regulator of 
SMN2 splicing. SAM68 binds SMN2 pre-mRNA in vivo near 
the 3′ ss of exon 7 and favors recruitment of hnRNP A1, while 
interfering with that of U2AF. Thus, our results suggest that 
SAM68 forms a repressive complex masking the 3′ ss and 
prevents its recognition by the spliceosome, causing exon 7 
skipping and expression of the unstable SMNΔ7 variant. Im-
portantly, ablation of Sam68 expression partially rescues SMN2 
splicing and expression, resulting in increased viability and 
amelioration of the phenotype of SMAΔ7 mice.
SMA is caused by the inability of the SMN2 gene to com-
pensate for the functional loss of SMN1 in patients (Arnold and 
Burghes, 2013; Nurputra et al., 2013). Because exon 7 skipping 
is the major cause of the decreased function of SMN2, char-
acterization of the splicing factors and molecular mechanisms 
regulating this splicing event is of crucial relevance for under-
standing the cause of SMA and for the design of therapeutic 
approaches (Lorson and Lorson, 2012). An advance in this di-
rection was provided by the identification of RBPs capable of 
modulating SMN2 splicing in cultured cells (Hofmann et al., 
2000; Hofmann and Wirth, 2002; Kashima and Manley, 2003; 
Kashima et al., 2007; Bose et al., 2008; Chen et al., 2008; Pe-
drotti et al., 2010; Singh et al., 2011). However, whether any of 
these splicing regulators contribute to the phenotype of SMA 
is still currently unknown, as a role in the onset or progression 
of SMA has not been demonstrated for any of them. This is 
particularly relevant because splicing is a tissue- and cell con-
text–specific combinatorial process (Fu and Ares, 2014). For 
instance, TRA2-β is a strong inducer of exon 7 inclusion in cul-
tured cells (Hofmann et al., 2000), but its conditional knockout 
showed no effect on SMN2 splicing in motor neurons (Mende 
et al., 2010). These findings highlight the complexity of al-
ternative splicing regulation in vivo and call for mechanistic 
studies to be performed directly in the cells or tissues that are 
relevant for the disease.
Our work was aimed at elucidating whether SAM68 is a 
physiological regulator of SMN2 splicing using an SMA mouse 
model. The SMAΔ7 mice used in our study display a severe 
form of the disease and die within 2 wk of birth (Le et al., 2005). 
Knockout of Sam68 expression in this strain resulted in sig-
nificant body weight gain and extended survival until 20 dpp. 
cated; the asterisk indicates an undefined band present in SMAΔ7 transgenic mice. (B) qPCR of SMN2Δ7 to quantify the dosage of transgenic SMN2Δ7 in 
hemizygous and homozygous transgenic animals. The data shown are from a single representative experiment, and values were normalized with Apolipo-
protein B mRNA. (C) Micrograph showing representative non-SMA and SMAΔ7 (SMA) mice that are either wild type (Sam68+/+) or knockout (Sam68−/−) 
for Sam68. (D) Kaplan-Meier survival curves of SMAΔ7/Sam68+/+ (n = 50) and SMAΔ7/Sam68−/− (n = 22). Statistical analysis was performed by the 
log-rank test (P < 0.0001). (E) Weight curves of non-SMA/Sam68+/+, non-SMA/Sam68−/−, SMAΔ7/Sam68+/+, and SMAΔ7/Sam68−/− mice. Plot shows 
mean ± SD of at least 15 mice for each group for each day analyzed. The p-values were determined by a two-way ANO VA test followed by Bonferroni’s 
multiple comparison posttest. # represents the p-value of the non-SMA/Sam68+/+ versus non-SMA/Sam68−/− comparison; § represents the p-value of the 
non-SMA/Sam68−/− versus SMAΔ7/Sam68−/− comparison; and * represents the p-value of the SMAΔ7/Sam68+/+ versus SMAΔ7/Sam68−/− compari-
son. For all comparisons, P < 0.05, P < 0.01, P < 0.001, and P < 0.0001 are represented by increasing symbols (from one to four). (F) Time required for 
pups to stand up after being placed on their sides for SMAΔ7/Sam68+/+ mice compared with SMAΔ7/Sam68−/− mice at 8 and 10 dpp (nd [nondetected] 
indicates experimental animals that never stood up during the test). Statistical analysis was performed by two-way ANO VA test followed by Bonferroni’s 
multiple comparison posttest (*, P < 0.05; ***, P < 0.001).
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Several pieces of evidence suggest that the impact of SAM68 
on the SMA phenotype directly relates to its ability to modulate 
SMN2 splicing in vivo. First, SAM68 is recruited near the 3′ 
ss of exon 7 in the brain of mice expressing the human SMN2 
transgene (Fig. 1 B). Furthermore, observations gathered using 
cell culture systems indicate that SAM68 interacts and coop-
erates with hnRNP A1 (Paronetto et al., 2007; Pedrotti et al., 
2010), one of the best-characterized repressors of SMN2 exon 
7 inclusion (Kashima and Manley, 2003; Kashima et al., 2007). 
Our findings now indicate that this cooperation is relevant in 
the context of SMA in vivo. Binding of hnRNP A1 in prox-
imity to the 3′ ss of exon 7 was strongly reduced in the ab-
sence of SAM68 (Fig. 1 C). In contrast, we found an inverse 
correlation between binding of SAM68 and U2AF65 to exon 
7 in vitro, with increased recruitment of this general splicing 
factor in brain extracts of Sam68-/- mice (Fig. 1 E). Thus, we 
propose a model in which SAM68 binds to the SMN2 pre-
mRNA near the 3′ ss of exon 7, favoring the recruitment of 
hnRNP A1. Formation of this inhibitory complex on the nascent 
pre-mRNA interferes with binding of U2AF and efficient rec-
ognition of the 3′ ss, thereby masking the exon and favoring its 
skipping from the mature mRNA.
Regulation of SMN2 splicing by SAM68 is likely to affect 
the SMA phenotype directly. We found that ablation of Sam68 
expression increased SMN2 exon 7 inclusion in the central ner-
vous system and in all peripheral tissues analyzed (Fig. 3 A). 
Furthermore, enhanced exon 7 splicing resulted in higher SMN 
expression (Fig. 3 B). SMN is a ubiquitous protein that localizes 
to both the cytoplasm and nucleus, where it accumulates in nu-
clear gems that are implicated in RNP assembly and maturation 
(Li et al., 2014). SMN gems were increased in motor neurons of 
the SMAΔ7/Sam68−/− spinal cord (Fig. 4, B and C), thus pro-
viding a robust readout for functional SMN. Moreover, ablation 
of Sam68 partially rescued the loss of motor neurons occurring 
in the spinal cord of SMAΔ7 mice (Fig. 5). Notably, SAM68 
expression is much higher in motor neurons than in surrounding 
cells of the spinal cord (Fig. 4 A), which may explain the partic-
ularly inefficient inclusion of exon 7 observed in motor neurons 
(Ruggiu et al., 2012). Collectively, these findings suggest that 
SAM68 physiologically participates in regulation of the dis-
ease-related SMN2 splicing and that amelioration of the SMA 
phenotype is likely a result of splicing-dependent stabilization 
of SMN protein in the absence of SAM68. However, the benefi-
cial effect of Sam68 ablation on the splicing of SMN2 could be 
Figure 3. Sam68 deletion rescues SMN2 splicing and expression in SMAΔ7 tissues. (A) qPCR analysis of exon 7–containing SMN2 transgene transcripts 
normalized to constant exon 6 in tissues of 10-dpp SMAΔ7/Sam68+/+ and SMAΔ7/Sam68−/− mice. Bar graph represents mean ± SD. n = 3. The p-value 
was determined by two-tailed t test (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001). (B) Western blot analysis of SMN protein expression in the indicated 
tissues of 10-dpp SMAΔ7/Sam68+/+ (wt) or SMAΔ7/Sam68−/− (ko) mice. Actin was used as a loading control. Quantification of the SMN band is shown 
at the bottom. Each point value represents the mean ± SD. n = 2. Cereb, cerebellum; ko, knockout; S.cord, spinal cord; wt, wild type.
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partially limited by the presence of SLM2, a homologous pro-
tein expressed in the brain (Ehrmann et al., 2013). SLM2 could 
partially complement the SAM68 splicing-repressive activity in 
Sam68−/− mice, as the two proteins bind almost identical RNA 
sequences (Galarneau and Richard, 2009). Moreover, we found 
that SLM2 also binds to the SMN2 pre-mRNA in vivo and 
can promote exon 7 skipping in transfected cells (unpublished 
data). Thus, as also suggested by the residual CLIP signal in 
Figure 4. Ablation of Sam68 rescues SMN assembly into nuclear gems in spinal cord motor neurons. (A) Immunodetection of SAM68 (blue) in ChAT-pos-
itive motor neurons (red) in the lumbar spinal cord (L1–L5) of 8-dpp non-SMA mice. DAPI was used for staining of nuclei. Motor neurons are indicated by 
arrows and surrounding cells by arrowheads. (B) Immunodetection of SMN gems (green) in ChAT-positive motor neurons (red) in the spinal cord (L1–L5) of 
8-dpp non-SMA, SMAΔ7/Sam68+/+, and SMAΔ7/Sam68−/− (SMA) mice. DAPI was used for staining of nuclei. Nuclear gems are indicated by arrow-
heads. Bars: (A and B) 20 µm; (insets) 10 µm. (C) Quantitative analysis of SMN gems in spinal motor neurons. The bar graph (mean ± SD; n = 3) shows the 
number of gems per 100 nuclei analyzed per sample (top) and the percentage of gem-positive motor neurons (bottom). Statistical analysis was performed 
by one-way ANO VA test followed by Bonferroni’s multiple comparison posttest (*, P < 0.05; ***, P < 0.001).
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Sam68−/− mice (Fig. S1 A), SLM2 might partially compensate 
for SAM68-dependent regulation of SMN2 splicing.
Knockout of Sam68 ameliorated hallmarks of the disease 
in SMAΔ7 mice. In addition to the rescue in SMN expression 
and in the number of motor neurons, SMAΔ7/Sam68−/− mice 
displayed an improvement in NMJ innervation and reduced 
muscle atrophy. Furthermore, ablation of Sam68 also affected 
other phenotypes described in SMA mouse models. In partic-
ular, SMAΔ7/Sam68−/− mice showed increased expression of 
IGF-1 pathway–related genes (Igf-1 and Igfals) in the liver, 
which was accompanied by a general improvement in the phys-
iology of the organ (Fig. S4, A–C). Improved function of the 
IGF-1 pathway in the liver was also elicited by antisense oligo-
nucleotide–mediated correction of SMN2 splicing, and it was 
supposed to contribute to improvement of the SMA phenotype 
(Hua et al., 2011). Although defects in peripheral organs have 
not been confirmed in SMA patients (Iascone et al., 2015), our 
observations suggest that increased expression of Igf-1 and Ig-
fals and the general improvement of liver function in SMAΔ7/
Sam68−/− mice might contribute to amelioration of the SMA 
phenotype observed in this study.
Although ablation of Sam68 expression caused a ubiqui-
tous increase in SMN expression and ameliorated several hall-
marks of SMA, we observed only a modest improvement in 
body weight and viability of SMAΔ7/Sam68−/− mice. Regard-
ing the limited increase in body weight, this is likely because of 
the smaller size of prepuberal non-SMA Sam68−/− mice (Fig. 2, 
C and E), similar to what was reported for adult Sam68−/− mice 
(Richard et al., 2005; Paronetto et al., 2009). However, the lim-
ited effect on viability might result from other phenotypes de-
scribed for this mouse. Sam68−/− mice have a relatively high 
perinatal lethality, with 30–35% of mice dying before weaning 
(Richard et al., 2005). Although the exact cause of decreased 
viability is still currently unknown, it is likely linked to the re-
ported changes in target RNA expression and splicing in several 
organs (Paronetto et al., 2009; Bianchi et al., 2010; Huot et al., 
2012), including the brain (Iijima et al., 2011). Thus, it is pos-
sible that other changes in gene expression and splicing caused 
by Sam68 ablation elicit deleterious effects that attenuate the 
benefit of the increased expression of SMN on the phenotype 
of SMAΔ7/Sam68−/− mice.
In conclusion, our work shows for the first time that di-
rect interference with the endogenous expression of a single 
splicing factor rescues SMN2 splicing and expression in an 
SMA mouse model, resulting in amelioration of the phenotype. 
Thus, these findings strongly support a direct role for SAM68 
in the pathology of SMA.
Materials and methods
Generation of transgenic mice and breeding strategy
Sam68+/− mice were generated by replacing exon 4 and part of exon 5 
with a neomycin-resistant gene cassette as previously characterized 
Figure 5. Ablation of Sam68 rescues motor neuron loss in the spinal cord of SMAΔ7 mice. (A) Schematic representation of a Nissl-stained spinal cord 
section of the lumbar spinal cord from 8-dpp non-SMA mice (right). The red circle highlights the ventral horn of the spinal cord analyzed. Bar, 250 
µm. (B) Higher magnification of sections of the ventral lumbar spinal cord from 8-dpp non-SMA, SMAΔ7/Sam68+/+, and SMAΔ7/Sam68−/− (SMA) 
mice. Motor neurons are indicated by arrowheads. Bar, 125 µm. (C) Bar graph representing motor neuron counts (mean ± SD; n = 3) in lumbar spi-
nal cord from mice described in B. Statistical analysis was performed by one-way ANO VA test followed by Bonferroni’s multiple comparison posttest 
(***, P < 0.001; ****, P < 0.0001).
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(Richard et al., 2005). The SMA mouse model used was FVB.
Cg-Tg(SMN2*delta7)4299Ahmb Tg(SMN2)89Ahmb Smn1tm1Msd/J 
(The Jackson Laboratory), hereafter referred to as SMAΔ7 mice. The 
SMAΔ7 mouse model was provided by F. Sangiuolo (University of Rome 
Tor Vergata, Rome, Italy). SMN2Δ7;SMN2;Smn+/− transgenic mice were 
crossed with Sam68+/− mice to obtain SMN2Δ7;SMN2;Smn+/−;Sam68+/− 
mice on an FVB/N × C57BL/6 hybrid background. Mice were inter-
bred to obtain SMAΔ7 mice (SMN2Δ7;SMN2;Smn−/−) that were wild 
type (Sam68+/+) or knockout (Sam68−/−) for Sam68. Breeding and 
maintenance of mice were done in accordance with the institutional 
guidelines of the University of Rome Tor Vergata and the approval 
of the Ethical Committee. Genomic DNA was isolated from the tail, 
amplified by PCR using the primers listed in Table S1, and genotyped 
as described previously (Le et al., 2005). Body weight and life span 
Figure 6. Ablation of Sam68 ameliorates innervation of NMJs. (A) NMJ immunofluorescence images from whole-mount FDB2 of 10-dpp non-SMA, 
SMAΔ7/Sam68+/+, and SMAΔ7/Sam68−/− (SMA) mice. Higher magnifications are shown in the bottom panels. Postsynaptic (AChRs stained with 
α-bungarotoxin; green), presynaptic (stained with α-synaptophysin; red), and motor neuron axons (stained with an antibody against the heavy chain of 
neurofilament; red) were visualized. Bars, 100 µm. Arrows point to innervated NMJs (yellow staining), and arrowheads point to denervated NMJs (green 
staining). (B) Bar graph showing the percentage of innervated (left) and denervated (right) NMJs in FDB2 of non-SMA, non-SMA/Sam68−/−, SMAΔ7/
Sam68+/+, and SMAΔ7/Sam68−/− mice (for all, n = 3). Quantification of NMJ innervation was performed on at least 100 optical sections for mice, with 
a step size of 3 µm from the whole FDB2 of each genotype. Data represent mean ± SEM. Statistical analysis was performed by one-way ANO VA followed 
by Bonferroni’s multiple comparison posttest (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant [P > 0.05]).
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recordings were performed every day until the natural death of the an-
imal. The righting test (recorded at 8 and 10 dpp) measured the time 
taken by mice to get back on their feet after being placed on the right 
side. Each mouse was subjected to five successive attempts separated 
by a 5-min rest period.
Motor neuron count in lumbar spinal cord
Anesthetized animals were submitted to intracardial perfusion with 
PBS followed by 4% PFA diluted in PBS. Coronal sections of the lum-
bar spinal cord (L1–L5) were cut with a cryostat at 30-µm thickness, 
and every seventh section was stained with Nissl substance. An op-
Figure 7. Skeletal muscle atrophy is ameliorated in the SMAΔ7/Sam68−/− mice. (A) Hematoxylin and eosin staining of triceps muscle sections from 10-dpp 
non-SMA, SMAΔ7/Sam68+/+, and SMAΔ7/Sam68−/− (SMA) mice. Bar, 100 µm. (B) Frequency distribution of muscle fiber areas (at least 2,000 for each 
genotype) of the experimental animals described in A. The colored lines and dotted line (non-SMA mice) represent the median value for each genotype: 
non-SMA mice (n = 3) median size = 531 µm2 and fiber size (mean ± SEM) = 568.76 ± 5.8 µm2; non-SMA/Sam68−/− mice (n = 3) median size = 557 
µm2 and fiber size (mean ± SEM) = 586.60 ± 5.7 µm2; SMAΔ7/Sam68+/+ median size = 327 µm2 and fiber size (mean ± SEM) = 342.32 ± 3.1 µm2; 
and SMAΔ7/Sam68−/− median size = 486 µm2 and fiber size (mean ± SEM) = 503.59 ± 4.6 µm2. Statistical analysis of the median values among groups 
was performed by one-way ANO VA test followed by Dunn’s multiple comparison posttest. (C) qPCR analysis of the expression of atrophy-related genes in 
quadriceps and lower leg muscles of mice described in B. Values (mean ± SD; n = 4) were normalized with Actin mRNA. Statistical analysis was performed 
by one-way ANO VA test followed by Bonferroni’s multiple comparison posttest. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not 
significant (P > 0.05). r.l., relative level.
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tical fractionator stereological design (West et al., 1991) was used to 
obtain unbiased estimates of the total number of motor neurons using 
the Stereo Investigator system (Stereo Investigator software, version 
4.04; MicroBrightField). A stack of MAC 5000 controller modules 
(Ludl Electronic Products) was configured to interface with a micro-
scope (BX 50; Olympus) with a motorized stage and a color digital 
camera (HV-C20; Hitachi) with a Pentium II PC workstation. A 3D 
optical dissector counting probe (x, y, and z dimensions of 30 × 30 × 10 
µm, respectively) was applied to a systematic random sample of motor 
neurons in the lumbar spinal cord. The region of interest was outlined 
using the 10× objective, whereas the 100× oil immersion objective was 
used for marking individual motor neurons. The total motor neuron 
number was estimated according to the formula given below:
  N = ∑ Q ×  1 ___ ssf ×  
1 ___ asf ×  
1 __ tsf . 
ΣQ, total number of motor neurons counted in all optical field sam-
ples of the lumbar spinal cord; ssf, section sampling fraction; asf, 
area sampling fraction; and tsf, thickness sampling fraction (defined 
by dissector height divided by estimated mean section thickness; 
Biamonte et al., 2009).
Histology and immunofluorescence
Hearts were embedded in tissue-freezing medium, snap frozen in nitro-
gen-cooled isopentane, and stained. Transversal sections of 7 µm were 
arbitrarily chosen and photomicrographed using AxioVision 3.1 soft-
ware (Carl Zeiss). IVS measurement was analyzed with ImageJ soft-
ware (v.1.42q; National Institutes of Health) as described previously 
(Shababi et al., 2010).
For NMJ analysis, the FDB2 and masseter muscles were dis-
sected and fixed in 4% PFA at 4°C for 180 min. Whole-mount muscles 
were immunostained with mouse antineurofilament (1:200; SMI-32; 
BioLegend) and rabbit antisynaptophysin (1:200; Thermo Fisher Sci-
entific). Neurofilaments were visualized with TRI TC AP donkey anti–
mouse IgG (1:200; Jackson ImmunoResearch Laboratories, Inc.), and 
synaptic vesicles were visualized with Cy5 AP donkey anti–rabbit IgG 
(1:400; Jackson ImmunoResearch Laboratories, Inc.) secondary anti-
body. AChRs were labeled with Alexa Fluor 488–conjugated α-bunga-
rotoxin (10 nM; Molecular Probes). Z-stack images were obtained at 
sequential focal planes 3 µm apart using a confocal microscope (Laser 
Scanning TCS SP2; Leica). Illustrated images are flattened projections 
of Z-stack images. Muscle innervation was analyzed with LAS AF Lite 
software (100 optical sections/genotype; Leica), and the innervation 
status of individual postsynaptic endplates was evaluated according to 
the extent to which the endplate overlaid with presynaptic components. 
For each muscle sample, 500 endplates were evaluated from randomly 
selected visual fields. Blind acquisition and analysis were performed 
using coded slides from three animals for each genotype.
For CSA analysis, triceps muscles were embedded in tis-
sue-freezing medium, snap frozen in nitrogen-cooled isopentane, and 
stained. A minimum of three transversal 7-µm sections were arbitrarily 
chosen from the middle region of each muscle and photomicrographed 
using AxioVision 3.1 software. The mean CSA of at least 2,000 myofi-
bers for each genotype was analyzed with ImageJ software.
For SMN gem detection, spinal cords were isolated from mice 
after perfusion, incubated overnight in 4% PFA solution, and trans-
ferred overnight in 30% sucrose in PBS at 4°C. 15-µm sections from 
the lumbar regions (L1–L5) were dissected, and one in every five sec-
tions was processed for immunofluorescence analysis. After heat-medi-
ated antigen retrieval (10-mM sodium citrate and 0.05% Tween 20, pH 
6.0; 10 min of microwaving), sections were incubated for 3 d with pri-
mary antibodies (prepared in 2% BSA in PBS containing 0.1% Triton 
X-100): mouse anti-SMN (1:100; BD), goat anti-ChAT (1:200; EMD 
Millipore), and rabbit anti-SAM68 (1:200; Santa Cruz Biotechnology, 
Inc.). Sections were incubated for 2 h at room temperature with second-
ary antibodies: Alexa Fluor 488 donkey anti–mouse IgG (1:200; Molec-
ular Probes), Alexa Fluor 555 donkey anti–goat IgG (1:200; Molecular 
Probes), and Alexa Fluor 647 donkey anti–rabbit IgG (1:200; Molecu-
lar Probes). DAPI was used for nuclear staining. Sections were exam-
ined by a confocal laser-scanning microscope (LSM700; Carl Zeiss).
Western blot analysis
Western blot analysis was performed as previously described 
(Paronetto et al., 2007). The primary antibodies (1:1,000) were rabbit 
anti-SAM68, mouse anti-ACT IN, mouse anti-GAP DH (all from Santa 
Cruz Biotechnology, Inc.), mouse anti-U2AF65 (Sigma-Aldrich), 
and mouse anti-SMN (BD).
Cell cultures, transfections, and cell extract preparation
Cell cultures, transfections, and sample preparation were performed by 
standard methods as previously described (Bielli et al., 2014). In brief, 
HEK293T cells were transfected with FLAG-SAM68 vector as indi-
cated using Lipofectamine 2000 (Invitrogen).
Biotin-RNA pull-down
Biotin-RNA pull-down experiments were performed using HEK293T 
cell nuclear extracts and SMN2 RNA probes in vitro synthesized from 
a PCR product amplified using primers (Table S1) and the plasmid PCI-
SMN2 in the presence of biotin-labeled deoxynucleotide (Roche) as de-
scribed previously (Pedrotti et al., 2010). Extracts were precleared for 
1 h on protein A–Sepharose beads (Sigma-Aldrich) and 1 h on strepta-
vidin-Sepharose beads (Sigma-Aldrich). Precleared extracts were then 
incubated with streptavidin-Sepharose beads in the presence of 0.1% 
BSA and biotinylated RNA probe for 2 h at 4°C under rotation. Beads 
were washed three times with washing buffer, and proteins were eluted 
in SDS sample buffer for Western blot analysis (Pedrotti et al., 2010).
UV-CLIP assays
CLIP assays were performed as previously described (Bielli et al., 
2014). In brief, dissociated brain tissue was irradiated three times on 
ice (100 mJ/cm2). Cell suspension was centrifuged at 4,000 rpm for 
3 min, and the pellet was incubated for 10 min on ice in lysis buffer (50-
mM Tris, pH 8.0, 100-mM NaCl, 1% NP-40, 1-mM MgCl2, 0.1-mM 
CaCl2, 0.5-mM Na3VO4, 1-mM DTT, protease inhibitor cocktail [Sig-
ma-Aldrich], and RNase inhibitor [Promega]). Samples were briefly 
sonicated and incubated with DNase (RNase-free; Ambion) for 3 min 
at 37°C and then centrifuged at 15,000 g for 3 min at 4°C. 1 mg of 
extract was treated with Proteinase K for 30 min at 55°C, and RNA 
was purified by standard procedure (input) or diluted to 1 ml with lysis 
buffer and immunoprecipitated using anti-SAM68 (Santa Cruz Bio-
technology, Inc.) and anti–hnRNP A1 (Santa Cruz Biotechnology, Inc.) 
antibodies or IgGs (negative control) in the presence of protein G mag-
netic Dynabeads (Novox; Life Technologies). 1,000 IU RNase I (Am-
bion) was added to immunoprecipitates and incubated for 2 h at 4°C 
under rotation. After stringent washes (Bielli et al., 2014), an aliquot 
(10%) was kept as a control of immunoprecipitation, while the rest was 
treated with 50 µg Proteinase K and incubated for 1 h at 55°C. RNA 
was then isolated by standard procedures.
qPCR analyses
qPCR was performed using LightCycler 480 SYBR green I Master and 
the LightCycler 480 System (Roche) according to the manufacturer’s 
instructions. For CLIP analyses, each sample was normalized with re-
 o
n
 O
ctober 5, 2015
jcb.rupress.org
D
ow
nloaded from
 
Published October 5, 2015
SAM68 is a physiological regulator of SMN2 splicing • Pagliarini et al. 13
spect to its input. SMN2 RNA associated with SAM68 or hnRNP A1 is 
represented as fold enrichment relative to IgG samples.
Statistical analyses
The quantitative data are expressed as the mean ± SD or SEM, as in-
dicated in the figure legends. Two-tailed Student’s t test and one-way 
and two-way analysis of variance (ANO VA) followed by Bonferroni’s 
multiple comparison posttest were performed using Prism 6 software 
(GraphPad Software). Kaplan-Meier survival data were analyzed 
with the log-rank test.
Online supplemental material
Fig. S1 shows the specific binding of SAM68 to SMN2 pre-mRNA and 
motor function analysis of non-SMA Sam68−/− mice. Fig. S2 shows the 
effects of Sam68 ablation on SMN and GEM IN2 expression in SMAΔ7 
mice and supporting data for Fig.  3.  Fig. S3 shows that ablation of 
Sam68 ameliorates innervation of NMJs in masseter muscle. Fig. S4 
documents amelioration of peripheral defects in the SMAΔ7/Sam68−/− 
mice. Table S1 represents the list of the oligonucleotides used as PCR 
or qPCR primers in this study. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.201502059/DC1.
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